SG47948A1 - Compounds for the treatment of neurodegenerative disorders - Google Patents
Compounds for the treatment of neurodegenerative disordersInfo
- Publication number
- SG47948A1 SG47948A1 SG1996005610A SG1996005610A SG47948A1 SG 47948 A1 SG47948 A1 SG 47948A1 SG 1996005610 A SG1996005610 A SG 1996005610A SG 1996005610 A SG1996005610 A SG 1996005610A SG 47948 A1 SG47948 A1 SG 47948A1
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- neurodegenerative disorders
- compounds
- pyridineethanamine
- alpha
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929207339A GB9207339D0 (en) | 1992-04-03 | 1992-04-03 | Pharmaceutical compound |
| GB929208290A GB9208290D0 (en) | 1992-04-15 | 1992-04-15 | Pharmaceutical compound having neuroprotective properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG47948A1 true SG47948A1 (en) | 1998-04-17 |
Family
ID=26300643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG1996005610A SG47948A1 (en) | 1992-04-03 | 1993-04-01 | Compounds for the treatment of neurodegenerative disorders |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0633879B1 (enExample) |
| JP (2) | JP3120810B2 (enExample) |
| KR (1) | KR100259567B1 (enExample) |
| CN (1) | CN1044367C (enExample) |
| AT (1) | ATE163925T1 (enExample) |
| AU (2) | AU3897693A (enExample) |
| CA (1) | CA2133427C (enExample) |
| CZ (1) | CZ288519B6 (enExample) |
| DE (1) | DE69317411T2 (enExample) |
| DK (1) | DK0633879T3 (enExample) |
| DZ (1) | DZ1677A1 (enExample) |
| ES (1) | ES2115055T3 (enExample) |
| FI (1) | FI105025B (enExample) |
| HU (1) | HU211529A9 (enExample) |
| IL (1) | IL105276A (enExample) |
| MA (1) | MA22866A1 (enExample) |
| MX (1) | MX9301935A (enExample) |
| MY (1) | MY110149A (enExample) |
| NO (1) | NO302170B1 (enExample) |
| NZ (1) | NZ251384A (enExample) |
| PL (1) | PL180014B1 (enExample) |
| RU (1) | RU2128650C1 (enExample) |
| SG (1) | SG47948A1 (enExample) |
| SK (1) | SK281258B6 (enExample) |
| TW (1) | TW282455B (enExample) |
| UA (1) | UA29437C2 (enExample) |
| WO (1) | WO1993020052A1 (enExample) |
| ZA (1) | ZA932415B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320273D0 (en) | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| ES2083972T3 (es) * | 1988-08-12 | 1996-05-01 | Astra Ab | Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras. |
| ZA942140B (en) | 1993-04-01 | 1994-10-03 | Fisons Corp | Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901237D0 (sv) * | 1999-04-06 | 1999-04-06 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| EP1202986B1 (en) * | 1999-07-28 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| WO2007017652A2 (en) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Arylakylamines for the treatment of cancer |
| US8013165B2 (en) * | 2008-12-24 | 2011-09-06 | Astrazeneca Ab | Ethanamine compounds and methods of using the same 545 |
| CN104114714A (zh) * | 2011-12-14 | 2014-10-22 | 阿斯利康(瑞典)有限公司 | Gabr-a2诊断 |
| KR102336426B1 (ko) | 2013-11-05 | 2021-12-08 | 아스트라제네카 아베 | Nmda 길항제 전구약물 |
| BR112022025900A2 (pt) * | 2020-06-23 | 2023-01-10 | Biohaven Therapeutics Ltd | Formulações tópicas de (1s)-1-fenil-2-piridin-2-iletanamina |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0320006A3 (en) * | 1987-12-11 | 1990-12-19 | Laboratoires Syntex | Uses of 1,4-dihydropyridines |
| ES2083972T3 (es) * | 1988-08-12 | 1996-05-01 | Astra Ab | Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras. |
-
1993
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 EP EP93907975A patent/EP0633879B1/en not_active Expired - Lifetime
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active Expired - Lifetime
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 CA CA002133427A patent/CA2133427C/en not_active Expired - Lifetime
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/en not_active Ceased
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
-
1994
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
-
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
-
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
-
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU610036B2 (en) | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis inflammation and as immunosuppressants | |
| IL110204A0 (en) | Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders | |
| WO1993000094A3 (en) | Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine | |
| EP0538898A3 (en) | Cytotoxic bicyclo (7.3.1)-tridec-4-ene-2,6-diyne compounds and process for the preparation thereof | |
| ZA932415B (en) | Compounds for the treatment of neurodegenerative disorders | |
| GB9226832D0 (en) | Pharmaceutical preparations for the treatment of psoriasis | |
| EP0626162A3 (de) | Krankenbett. | |
| CA2135709A1 (en) | Melatonin derivatives for use in treating sleep disorders | |
| EP0592903A3 (en) | Use of Ancrod in the manufacture of medications for the treatment of restenosis. | |
| CA2135710A1 (en) | Melatonin derivatives for use in treating desynchronization disorders | |
| ZA933151B (en) | Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds. | |
| HRP931016A2 (en) | Thienothiazin derivatives, process for the preparation and application thereof | |
| ZA935154B (en) | Use of 1,2,5-oxadiazole-2-oxides for the treatment of erectile dysfunctions | |
| GB9103278D0 (en) | Drug for the treatment of dermatitis | |
| ZA949347B (en) | 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceutical agents containing these compounds and process for their production. | |
| AU6581294A (en) | Ethanolamine derivatives useful for the treatment of gastrointestinal disorders | |
| EP0583136A3 (en) | Piperidino-3,4-dihydrocarbostyryl compounds for the treatment of ischemic disorders | |
| GR3036226T3 (en) | 6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same | |
| IL89901A0 (en) | Strobilurine derivatives | |
| AU3084992A (en) | 1,4-dihydropyridines for use in the treatment of dermatosis | |
| AU4825993A (en) | New compounds for use in the treatment of cancer | |
| GB2270313B (en) | 1,3,4-Benzotriazepin-5 (4H)-one derivatives and process for the preparation thereof | |
| AU7183298A (en) | Melatonin derivatives for use in treating desynchronization disorders | |
| GR920100423A (el) | Ανταγωνιστές 5-ΗΤ4 κινολιζιδινυλ εστέρος. | |
| ZA934785B (en) | 17-halogeno-4-azaandrostene derivatives and process for the preparation thereof. |